Fox Chase Cancer Center Announces Strategic Partnership with SpotitEarly Bolstering the Validity of its Breakthrough Early Cancer Detection Technology

PHILADELPHIA (January 22, 2025) -SpotitEarly, an early cancer detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, today announced a strategic partnership with Fox Chase Cancer Center.

SpotitEarly's partnership with Fox Chase, a nationally recognized leader in oncology innovation, with a history of accelerating cancer breakthroughs, includes plans for clinical trials to further validate its test. SpotitEarly is also dedicating a portion of its company equity to Fox Chase Cancer Center, representing its commitment to collaboration and advancing early cancer detection research.

Under the terms of the master research collaboration agreement, Fox Chase will lead a multi-year, investigator-initiated clinical trial evaluating the performance of SpotitEarly's exhaled-breath test in patients undergoing standard-of-care evaluation for suspected lung cancer. The collaboration combines direct research funding with a long-term strategic partnership model designed to align incentives and accelerate clinical translation, with the potential to expand this research framework to additional cancer indications and future applications beyond the initial lung cancer program.

"At Fox Chase, we are committed to pushing the boundaries of cancer research through bold and collaborative partnerships," said Sangeeta Bardhan Cook, PhD, MBA, and Chief Innovation Officer, Fox Chase Cancer Center. "SpotitEarly brings an unconventional yet scientifically promising approach to early detection, and we see tremendous potential in their innovative product and technology when combined with our robust clinical expertise. Together, we will open new doors to earlier diagnoses and, ultimately, better outcomes for patients."

The news of this collaboration with Fox Chase comes on the heels of SpotitEarly announcing a partnership with Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, along with plans for a series of joint clinical trials in July. The pace and distinction of these U.S.-based partnerships since entering the market in May highlight the growing confidence in SpotitEarly's approach to early cancer detection.

"Working with Fox Chase Cancer Center was a natural next step for our organization as we continue to grow our footprint in the states," said Shlomi Madar, PhD, CEO of SpotitEarly. "As a leader in cancer research, their team will provide us with access to a vast network of physicians and resources to collaborate on groundbreaking clinical trials and treatments, moving forward our mission of increasing accessibility to early cancer detection technology for millions."

SpotitEarly's proprietary LUCID bio-AI hybrid platform combines artificial intelligence and machine learning with trained canine scent detection, using integrated sensors to continuously monitor canine behavioral and physiological signals. These signals are translated into a standardized, repeatable approach for identifying cancer-associated signals in breath, enabling non-invasive screening focused on earlier detection, when treatment options are most effective. To learn more about how SpotitEarly is making early cancer detection more accessible and improving survival outcomes, visit www.spotitearly.com.